This company provides integrated multi-omics services spanning proteomics, metabolomics, and lipidomics for dynamic biomarker discovery. They utilize mass spectrometry and AI-driven biocomputational analysis to generate deep biological insights relevant to drug development and disease research. Their platform supports target identification, translational studies, and clinical biomarker validation across diverse sample types.
Funding
$36.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biopharmaceutical companies face challenges in gaining comprehensive insights into health, disease mechanisms, and drug responses due to limitations in traditional biomarker analysis. Conventional methods often lack the throughput and scale needed to analyze thousands of biomarkers from large sample sets, hindering effective precision drug development.
Solution
Sapient provides multi-omics services, including metabolomics, lipidomics, and proteomics, leveraging high-throughput mass spectrometry to generate and analyze thousands of biomarkers from large sample sets. Their integrated approach enables a comprehensive view into the dynamic factors modulating health, disease, and drug response across individuals and over time. Sapient's services facilitate the identification of novel drug targets, robust biomarkers, and clinical signatures through AI-driven analysis and their proprietary DynamiQ™ datasets. The platform supports biomarker discovery, validation, and translation, offering a pipeline that spans preclinical to clinical applications.
Target Audience
The primary customers are biopharmaceutical companies involved in target identification, drug development, population health studies, and disease research.
Features
- High-throughput mass spectrometry systems capable of processing over 5,000 samples per day
- Discovery metabolomics and lipidomics services measuring over 15,000 small molecule biomarkers per biosample
- In-house library of over 10,000 reference standards for robust metabolite identification
- Discovery proteomics services providing deep coverage of the blood and tissue proteome, measuring thousands of proteins and post-translational modifications (PTMs)
- Targeted protein assays with an expansive menu of over 12,000 off-the-shelf assays and custom assay development
- NULISA™ assays for detection of low-abundance cytokines, chemokines, and neuroinflammatory mediators
- Biocomputational analysis using advanced AI and ML tools for biomarker discovery, pathway mapping, and predictive modeling
- DynamiQ™ Insights Engine, a longitudinal multi-omics database with real-world data from tens of thousands of biosamples